Aerocrine AB announces change in the board of directors

Solna (Sweden) – December 12, 2014 – Aerocrine AB (Nasdaq Stockholm: AERO) today
announces that board member Staffan Lindstrand has resigned from the board of
directors effective immediately.
For more information, please contact:

Scott Myers, Chief Executive Officer, Aerocrine AB, +46 768 788 379, +1 970 368
0336

About Aerocrine

Aerocrine AB is a medical product company focused on the improved management and
care of patients with inflammatory airway diseases. As the pioneer and leader in
technology to monitor and manage airway inflammation, Aerocrine markets NIOX
MINO® and NIOX VERO®. Both products enable fast and reliable management of
airway inflammation and may therefore play a critical role in more effective
diagnosis, treatment and follow-up of patients with inflammatory airway diseases
such as asthma. Aerocrine is based in Sweden with subsidiaries in the U.S.,
Germany, Switzerland and the U.K. Aerocrine shares were listed on the Stockholm
Stock Exchange in 2007. For more information, please visit www.aerocrine.com and
www.niox.com.

Aerocrine is required to disclose the information provided herein pursuant to
the Securities Markets Act and/or the Financial Instruments Trading Act. The
information was submitted for publication at 5:00 p.m. on December 12, 2014